Wegovy and Zepbound are changing how Americans get health care
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Wegovy and Zepbound are changing how Americans get health care" is generating significant coverage in the Health category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo, Fortune, KY3 and NBC Connecticut. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 85d ago.
Quick answers
Why is "Wegovy and Zepbound are changing how Americans get health care" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- They lost weight with a GLP-1. Then their spending changed in ways they never saw coming. Yahoo · 89d ago
- 'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way Fortune · 89d ago
- Researchers find new benefits, risks in GLP-1 weight loss drugs KY3 · 89d ago
- Beyond the Scale: A discussion on the research, risks, benefits, and impact of GLP-1s NBC Connecticut · 89d ago
- How GLP-1 weight loss drugs are reshaping the healthcare industry Fox Business · 89d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
Credit card debt hits record high as Americans struggle with cost-of-living
U.S. credit card debt hit a record $1.285 trillion in the third quarter of 2026, up $52 billion from a year earlier, while delinquency gaps between low- and high-income neighborhoods widened sharply.